Rob B Van Der Luijt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2403114/publications.pdf

Version: 2024-02-01

24 papers 3,360 citations

430442 18 h-index 610482 24 g-index

24 all docs

24 docs citations

times ranked

24

7444 citing authors

#	Article	IF	CITATIONS
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
2	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
5	Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. Nature Biotechnology, 2014, 32, 1019-1025.	9.4	231
6	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	3.9	118
7	MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Medicine, 2016, 14, 182.	2.3	95
8	The <i>BRCA1</i> c. 5096G> A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	1.5	50
9	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49
10	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
11	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
12	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	1.4	38
13	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
14	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. Journal of Medical Genetics, 2015, 52, 224-230.	1.5	32
15	Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial. Genetics in Medicine, 2016, 18, 137-144.	1.1	28
16	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
17	Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trial. BMC Cancer, 2011, 11, 6.	1.1	22
18	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	0.8	21

#	Article	IF	CITATIONS
19	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
20	Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands. Familial Cancer, 2017, 16, 271-277.	0.9	16
21	Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. European Journal of Endocrinology, 2019, 180, K15-K19.	1.9	16
22	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. Familial Cancer, 2016, 15, 607-616.	0.9	11
23	The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?. European Journal of Human Genetics, 2018, 26, 848-857.	1.4	5
24	Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences. Hereditary Cancer in Clinical Practice, 2021, 19, 9.	0.6	3